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Dr David C. Rice (Houston, Tex). This study is important for a
number of reasons. First, it adds to the voluminous body of data
showing that VATS lobectomy, at least for straightforward
resections, is safer for patients than open lobectomy, especially
for high-risk patients. Second, it is the only large study of this
type that has been able to document a decreased operative
mortality associated with VATS. Finally, it has demonstrated
continued increased adoption of VATS lobectomy by surgeons
affiliated with the Society of Thoracic Surgeons. Almost one
half of the lobectomies in this study were performed by VATS,
double the number just 6, 7 years ago.
The study had several obvious limitations, not the least of which
was that apart from the spirometric measurements, we know
nothing of the functional assessments that these high-risk
patients underwent that might have allowed or disallowed their
candidacy for surgery. Thus, the general applicability to an overall
population of patients with lung cancer at high risk is debatable.
You appropriately dealt with the odd clumping of VATS
segmentectomy with lobectomy, and I applaud your use of
propensity analysis. I have 4 questions.
I understand that patients who underwent sleeve lobectomy
were excluded from the analysis, but did you also exclude patients
undergoing more extensive procedures such as bilobectomy, chest
wall resection, diaphragm resection, or redo resections that might
have negatively biased the open group?
Second, the Duke University group published a study last year
that used the same database for an earlier cohort and analyzed by
the same biostatistical group that showed a greater incidence of
pulmonary morbidity but a relatively less overall reduction in
mortality related to VATS. How do you account for the differences
between that study and yours?
Third, it has been shown by several other studies that the
operative outcomes after lobectomy are highly related to center
volume. Is it possible that the centers that performed VATS were
also the high-volume centers and did you or do you plan on
studying hospital volume as a possible contributing factor?
Finally, if the ppoFEV1 and ppoDLCO of <40% were not
necessarily associated with prohibitive morbidity after VATS
lobectomy, at what value should we stop?
I congratulate you on an excellent presentation and thank you
for allowing me to review the report and slides well in advance.
Dr Burt. Thank you, Dr Rice, for reviewing the report and for
your insightful questions.
In terms of your first question, we did exclude patients who
were undergoing sleeve lobectomy and we did exclude patients
who underwent bilobectomy. We included patients who were
undergoing a reoperation; that was about 5.5% of the cases. That
was controlled for in our multivariate analysis and was balanced
in our propensity analysis. Your point on the additional chest28 The Journal of Thoracic and Cardiovascular Surgewall resection and diaphragm resection is a good one, and although
these probably represented a low overall fraction of lobectomies,
they were not controlled for in the present study.
Then your second question is about the report by Drs Ceppa and
Onaitis last year in the Annals of Surgery.What they showed, using
mostly the previous version of the Society of Thoracic Surgeons
database was that patients who underwent open lobectomy had
increased cardiopulmonary complications if their FEV1 was
<60%. Thus, patients whose FEV1 was<60% who underwent
open lobectomy had greater rates of postoperative complications
than a nonmatched VATS comparison group. Their overall rate
of complications was about 22% in the open group and 18% in
the VATS group, greater than our overall complication rate. I did
not show it in the slides, but our overall rate of cardiopulmonary
complications was 13% in the open group and 7% in the VATS
group, which was significantly lower. I believe that this was
probably a function of time. We considered the period from
2009 to 2011, and the previously quoted study was from 2002 to
2009 or 2010, and it is likely that our complication rates have
been decreasing over time.
Your third point is about center volume. As you alluded, it has
been shown that for a variety of operations, higher volume centers
have had lower rates of operative risk, and we did not consider this
specifically in our study. However, I will tell you that I did survey
all the input data from the 186 institutions that contributed to the
Society of Thoracic Surgeons database during the study period,
and no one or several institutions disproportionately contributed
to the number of VATS operations.
Then, your final question is really, I guess, the crux of our
report, which is how should these data be interpreted. It was not
our intention to decide a numeric value for which there is a
prohibitive, or high, or low risk of surgery. That is why I showed
the data in the figure so that practicing thoracic surgeons can
make an informed decision of the risk at different levels of ppo.
As you also alluded, this is only 1 variable in the equation when
evaluating patients, and it is a combination of clinical judgment
and experience and an evaluation of patient frailty and a number
of other patient-related factors that are just as important or more
important than any of the numbers I have shown you. However,
I hope I did convince you that patients with compromised
pulmonary function can undergo VATS lobectomy with relative
safety.
Dr Scott Swanson (Boston, Mass).Bryan, that was an excellent
presentation. You have obviously been well trained. My question
for you is, do you think these data about marginal reserve related
to DLCO is generalizable to other types of marginal reserve,
whether cardiac or age or other evidence of frailty, such that
VATS would be an improvement in those groups as well?
Number 2, you are a practicing cardiothoracic surgeon. How do
you use these data? Do you believe that VATS lobectomy is a
paradigm shift and allows you to perform operations that you
might not have had you only been able to perform open
thoracotomy?
Dr Burt. In terms of your first question, these are multivariate
predictors; thus, it takes into account all the other variables. Others
have shown that if you have something else in addition to a
compromised pulmonary function, such as increased age or
worsening cardiac function, your risk can double. Thus, I thinkry c July 2014
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evaluating a patient.
Regarding your second question about a paradigm shift, I think
so. Obviously, less trauma and better pulmonary recovery
occurs after VATS lobectomy. I believe these data represent an
improvement in the care of patients with lung cancer who would
previously not have been able to undergo lobectomy secondary
to compromised pulmonary function and who now could
potentially be offered VATS lobectomy.
Dr Joel D. Cooper (Philadelphia, Pa). Dr Burt, I enjoyed your
report, and it is obvious that a great deal of work and data mining
went into it. Although I disagree with your conclusion, I think the
most important point is being missed. It is not a question of VATS
versus open. We could argue that all day, and I happen to disagree
with you. What I am mainly concerned about however, are other
issues.
Your abstract read ‘‘predicted postoperative values of<40% of
normal are considered prohibitive for lobectomy owing to high
rates of mortality and cardiopulmonary complications.’’ That
simply is not true, and this is not the first report that has made
that statement. What you are saying is that a preoperative FEV1
of 50% of the predicted value is considered too high a risk for
lobectomy. You do not believe that, do you? The results you
have reported for the open procedures show, overall, a rather
good result. Thus, I am concerned about such a misleading
statement, and my first question is, do you really believe it,
regardless of whether the procedure is to be VATS or open?
Dr Burt. I submit that statement might have been a little
aggressive in the abstract, which I did not actually end up including
in the report. What I do believe and what the American College of
Chest Physicians recommends is that a ppo value of <40%
identifies a patient at high risk, and their national guidelines would
suggest that patients with a ppoFEV1 of<40% deserve additional
workup, possibly cardiopulmonary exercise testing. They have
stated that a ppoFEV1 of<30% is a prohibitive risk and that those
patients should perhaps undergo sublobar resection or stereotactic
body radiotherapy instead of lobectomy. So, I do not believe that a
ppo of<40% is prohibitive risk, but I believe it does identify
patients at very high risk.
If you look at the data, the mortality was 5 times greater among
the>600 matched patients with a ppoFEV1 of<40% undergoing
open compared with VATS lobectomy. To me, that is a pretty
impressive statistic.
Dr Cooper. But with VATS, you report a 5 times greater
mortality when you operate on patients who have a predicted post-
operative FEV1 of 20% to 30% compared with your group ofThe Journal of Thoracic and Cpatients whose predicted postoperative FEV1 was<20%. So, there
are many ways one can interpret or play with the data.
The second point is I do not believe that the prediction of the
postoperative FEV1 is helpful, especially as one goes to lower
and lower values of the FEV1. The patients with the poorest
preoperative FEV1s usually have the most severe emphysema.
In those patients, the actual postoperative FEV1 after lobectomy
usually increases, not diminishes, because of the so-called volume
reduction effect of removing a lobe that has a significant degree of
emphysematous destruction. Therefore, why use the prediction of
the postoperative value in such patients? Returning to my first
point, what you are suggesting is that a patient with an actual
FEV1 of <50% of the predicted value would represent a
prohibitive risk of morbidity and mortality after lobectomy. This
leads to my last and greatest concern. By accepting as your prem-
ise, someone else’s guidelines, especially nonsurgeons’ opinions
as to what does and does not constitute prohibitive risk, we are
abrogating our responsibility as thoracic surgeons. You know as
well as I do that many factors must be considered in selecting
appropriate candidates for lung resection. These include the
severity, pattern, and distribution of the emphysematous changes,
the overall performance status of the patient, how much of the
reduced FEV1 has resulted from airway disease and how much
from emphysema, and so forth. We reported 10 years ago at this
meeting on 21 consecutive patients with a FEV1 <30% who
underwent resection of lung cancer, 18 of the 21 being
lobectomies. None of these patients had died within the first
12 months. Thus, my question is what are we going to do to change
the misconception in the nonthoracic community as to what does
and does not constitute a prohibitive risk of morbidity and
mortality?
Dr Burt. I would like to reply to your first point about the
emphysema. It is clear that the FEV1 is not as accurate in
patients with chronic obstructive pulmonary disease, and 1
limitation of the study was that we could not know which
nonfunctional emphysematous lobes were removed. These
patients perhaps benefited from the lung volume reduction
surgery effect of a lobectomy. So, that is a limitation of the study.
However, the DLCO has been shown, even in patients with
compromised pulmonary function or decreased air flow or
chronic obstructive pulmonary disease, to still predict operative
mortality.
I understand your point. I think we all have to make our own
decisions. I am not suggesting that we follow others’ guidelines,
but I think there is a clear separation between those undergoing
VATS and open lobectomy based on at least these parameters.ardiovascular Surgery c Volume 148, Number 1 29
